HR Execs on the Move

Foghorn Therapeutics

www.foghorntx.com

 
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.foghorntx.com
  • 500 Technology Square Suite 700
    Cambridge, MA USA 02139
  • Phone: 617.586.3100

Executives

Name Title Contact Details
Tara Maduri
Director, Accounting and Finance Profile
Carlos Costa Mateu
Senior Vice President, People and Organization Profile
Alena Reva
Senior Director of People Operations Profile

Similar Companies

DOWNTOWN BRONX MEDICAL ASSOCIATES

DOWNTOWN BRONX MEDICAL ASSOCIATES is a Bronx, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PickPoint Corporation

PickPoint Corporation is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

bodyevolutionorg

bodyevolutionorg is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.

GROVE INSTRUMENTS

GROVE INSTRUMENTS is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Worcester, MA. To find more information about GROVE INSTRUMENTS, please visit www.groveinstruments.com